Cutaneous Squamous Cell Carcinoma: Emerging Therapeutic Options: Recent Episodes
ReachMD
Over a million cases of Cutaneous Squamous Cell Carcinoma are diagnosed annually. For eligible patients, surgery has been the primary treatment modality in part due to high cure rates. Patients ineligible for surgery have often been left with a dismal set of options. New therapeutic modalities, however, are now changing the way clinicians’ approach cSCC, particularly for tumors unamenable to surgery. Join medical oncologists, dermatologists, and Mohs surgeons as they explore the safety and efficacy of emerging systemic therapies, including conversations with patients and caregivers.
Host: Chrysalyne D. Schmults, MD, MSCE (Chair)
Guest: Omid Hamid, MD
Guest: Anokhi Jambusaria, MD, MSCE, FAAD
Please note: This activity is no longer available for continuing education credit.
Available treatment options for cutaneous squamous cell carcinoma (cSCC) are expanding and involving more interdisciplinary dialogue. This slides/audio presentation features 3 clinical case scenarios with feedback and commentary by a medical oncologist, surgeon, and dermatologist exploring topics in immunotherapy, Mohs surgery, and complex patient presentations.
Host: Chrysalyne D. Schmults, MD, MSCE (Chair)
Guest: Omid Hamid, MD
Guest: Anokhi Jambusaria, MD, MSCE, FAAD
Please note: This activity is no longer available for continuing education credit.
The recent approval of the first immunotherapeutic agent for cutaneous squamous cell carcinoma (cSCC) is changing the way healthcare providers treat patients with inoperable cSCC. In this roundtable discussion, a cSCC survivor draws upon his experience with the cancer when surgery and chemotherapy failed him, as our multidisciplinary faculty panel focus on how to optimally select patients with cSCC for treatment with immunotherapy.